Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher S Hourigan

Showing results (21-30 of 145) with videos related to

Pageof 15
Sort By:
Therapeutic Advances in Hematology|May 2, 2018
Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practiceChristin B DeStefano, Christopher S Hourigan
Cancer Discovery|December 12, 2013
Personalized therapy for acute myeloid leukemiaChristopher S Hourigan, Judith E Karp
The New England Journal of Medicine|December 14, 2016
Cord-Blood Transplantation in Patients with Minimal Residual DiseaseChristopher S Hourigan, Torsten Haferlach, Peter Hokland
Expert Review of Hematology|October 31, 2015
Precision medicine for acute myeloid leukemiaCatherine Lai, Judith E Karp, Christopher S Hourigan
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 4, 2014
Reprint of: Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantationChristopher S Hourigan, Philip McCarthy, Marcos de Lima
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2013
Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantationChristopher S Hourigan, Philip McCarthy, Marcos de Lima
JAMA|July 11, 2023
DNA Sequencing in Adults With Acute Myeloid Leukemia to Detect Residual Disease Prior to Hematopoietic Cell Transplant-ReplyGege Gui, Laura W Dillon, Christopher S Hourigan
British Journal of Haematology|December 6, 2019
Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemiaJack Ghannam, Laura W Dillon, Christopher S Hourigan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2021
Measurable Residual Disease Before Reduced-Intensity Allogeneic Transplantation in Patients With Myeloid MalignancyGege Gui, Laura W Dillon, Christopher S Hourigan
Current Hematologic Malignancy Reports|October 14, 2017
The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid LeukemiaFrancesco Buccisano, Christopher S Hourigan, Roland B Walter
Pageof 15

Showing results (21-30 of 145) with videos related to

Sort By:
Pageof 15
Therapeutic Advances in Hematology|May 2, 2018
Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practiceChristin B DeStefano, Christopher S Hourigan
Cancer Discovery|December 12, 2013
Personalized therapy for acute myeloid leukemiaChristopher S Hourigan, Judith E Karp
The New England Journal of Medicine|December 14, 2016
Cord-Blood Transplantation in Patients with Minimal Residual DiseaseChristopher S Hourigan, Torsten Haferlach, Peter Hokland
Expert Review of Hematology|October 31, 2015
Precision medicine for acute myeloid leukemiaCatherine Lai, Judith E Karp, Christopher S Hourigan
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 4, 2014
Reprint of: Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantationChristopher S Hourigan, Philip McCarthy, Marcos de Lima
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2013
Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantationChristopher S Hourigan, Philip McCarthy, Marcos de Lima
JAMA|July 11, 2023
DNA Sequencing in Adults With Acute Myeloid Leukemia to Detect Residual Disease Prior to Hematopoietic Cell Transplant-ReplyGege Gui, Laura W Dillon, Christopher S Hourigan
British Journal of Haematology|December 6, 2019
Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemiaJack Ghannam, Laura W Dillon, Christopher S Hourigan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2021
Measurable Residual Disease Before Reduced-Intensity Allogeneic Transplantation in Patients With Myeloid MalignancyGege Gui, Laura W Dillon, Christopher S Hourigan
Current Hematologic Malignancy Reports|October 14, 2017
The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid LeukemiaFrancesco Buccisano, Christopher S Hourigan, Roland B Walter
Pageof 15